Curated News
By: NewsRamp Editorial Staff
April 20, 2026
Helus Pharma CEO Steps Down, Co-founder Takes Interim Role Amid Key Trial
TLDR
- Helus Pharma's leadership transition ensures continuity for upcoming Phase 3 trial results, potentially creating shareholder value through clinical advancement.
- Helus Pharma appointed its co-founder as interim CEO to maintain focus on clinical pipeline development while searching for a permanent successor.
- Helus Pharma's clinical trials for novel mental health treatments aim to provide durable improvements for people suffering from depression and anxiety.
- Helus Pharma develops synthetic molecules called NSAs that activate serotonin pathways to promote neuroplasticity for mental health treatment.
Impact - Why it Matters
This leadership transition at Helus Pharma is crucial as it occurs during a pivotal moment for the company's clinical pipeline, particularly with the upcoming topline data from the APPROACH trial of HLP003, a potential breakthrough in treating major depressive disorder. Mental health disorders affect millions globally, often with limited effective treatments, making advancements in this field highly significant. If successful, Helus Pharma's NSAs could offer new hope for patients suffering from depression and anxiety, potentially improving quality of life and reducing healthcare burdens. For investors, this change aims to ensure stability and focus on long-term value, which is vital in the volatile biotech sector where clinical trial outcomes can dramatically impact stock performance and future funding. The interim leadership by a co-founder suggests a commitment to continuity, but the search for a permanent CEO will be closely watched, as it could influence the company's strategic direction and ability to bring innovative therapies to market, ultimately benefiting both public health and shareholder returns.
Summary
Helus Pharma, the commercial operating name of Cybin Inc., has announced a significant leadership transition as Michael Cola steps down as Chief Executive Officer effective immediately at the request of the Board. Co-founder and Executive Chairman Eric So has been appointed as Interim CEO while the company conducts a search for a permanent successor. This strategic move is designed to ensure continuity as Helus Pharma advances its clinical pipeline, particularly focusing on the anticipated fourth-quarter topline data readout from the APPROACH trial of HLP003. The company emphasizes maintaining its commitment to long-term value creation for both patients and shareholders during this period of change.
Helus Pharma is a clinical-stage pharmaceutical company dedicated to helping minds heal by developing proprietary NSAs (novel serotonergic agonists). These synthetic molecules are engineered to activate serotonin pathways believed to promote neuroplasticity, addressing the substantial unmet needs of individuals suffering from depression, anxiety, and other mental health conditions. With class-leading data, the company aims to revolutionize the treatment landscape through NSAs that provide durable mental health improvements. Their current pipeline includes HLP003, a proprietary NSA in Phase 3 clinical development for adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder.
For more detailed information, readers can visit the full press release at https://ibn.fm/3Gp8X. The company operates across Canada, the United States, the United Kingdom, and Ireland, and updates are available through their website at www.helus.com or via social media platforms like X, LinkedIn, YouTube, and Instagram. This news is disseminated through InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio at IBN, which provides advanced wire-grade press release syndication and other corporate communications solutions to enhance brand awareness and reach a wide audience of investors and the general public.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma CEO Steps Down, Co-founder Takes Interim Role Amid Key Trial
